RST-001 Phase I/II Trial for Advanced Retinitis Pigmentosa



Status:Recruiting
Conditions:Ocular
Therapuetic Areas:Ophthalmology
Healthy:No
Age Range:18 - Any
Updated:4/5/2019
Start Date:December 14, 2015
End Date:October 31, 2033
Contact:Clinical Trials Registry Team
Email:IR-CTRegistration@Allergan.com
Phone:877-277-8566

Use our guide to learn which trials are right for you!

Phase I/IIa, Open-Label, Dose-Escalation Study of Safety and Tolerability of Intravitreal RST-001 in Patients With Advanced Retinitis Pigmentosa (RP)

RST-001 is a gene therapy given as an injection into the eye.


Inclusion criteria:

Participants must meet all of the following criteria.

1. Age >= 18 years

2. Signed and dated written informed consent obtained from the patient.

3. Ability to comply with testing and all protocol tests.

Exclusion criteria:

Any one of the following will exclude patients from being enrolled into the study:

1. Unable or unwilling to meet requirements of the study;

2. Participation in a clinical study (ocular or non-ocular) with an investigational drug,
agent or therapy in the past six months
We found this trial at
4
sites
Cincinnati, Ohio 45242
Phone: 513-569-3669
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Dallas, Texas 75231
Phone: 214-363-3911
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Durham, North Carolina 27710
Phone: 919-681-3987
?
mi
from
Durham, NC
Click here to add this to my saved trials
San Francisco, California 94143
Phone: 415-514-4240
?
mi
from
San Francisco, CA
Click here to add this to my saved trials